![Sigal Fattal](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Sigal Fattal
Director of Finance/CFO at CHEMOMAB THERAPEUTICS LTD.
Net worth: 684 $ as of 2024-06-29
Sigal Fattal active positions
Companies | Position | Start | End |
---|---|---|---|
CHEMOMAB THERAPEUTICS LTD. | Director of Finance/CFO | 2023-05-31 | - |
Corporate Officer/Principal | 2021-11-07 | 2023-05-31 | |
ECtel Ltd.
![]() ECtel Ltd. Information Technology ServicesTechnology Services ECtel, Ltd. engages in the development and marketing of fraud prevention and revenue assurance solutions for circuit-switched and packet-switched wireline and wireless networks. The company offers revenue assurance, fraud prevention and revenue assistance solutions, which consist of proprietary software and hardware components, as well as off-the-shelf hardware and software components. Its solutions equip telecommunications service providers with data gathering and analysis capabilities by detecting and preventing fraud; supporting revenue assurance, including call leakage detection; enabling to settle interconnect disputes between operators; monitoring network usage, and providing traffic trend reports. ECtel sells its products through its direct sales force and marketing staff, as well as through representatives, distributors and sales consultants in Israel, the Americas, Europe, Asia Pacific and other countries. The company, formerly known as ECI Telesystems, Ltd., was established in 1990 and is headquartered in Rosh Ha'ayin, IL. | Director of Finance/CFO | - | - |
Career history of Sigal Fattal
Former positions of Sigal Fattal
Companies | Position | Start | End |
---|---|---|---|
BiomX Ltd.
![]() BiomX Ltd. Pharmaceuticals: MajorHealth Technology BiomX Ltd. engages in the development of customized phage therapies designed to target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease and colorectalcancer, as well as bacteria that affect the appearance of the skin. The company was founded by Eran Elinav, Timothy K. Lu, and Rotem Sorek on March 3, 2015 and is headquartered in Ness Ziona, Israel. | Director of Finance/CFO | 2017-02-28 | 2019-11-30 |
EVOGENE LTD. | Director of Finance/CFO | 2012-05-31 | 2015-12-31 |
Chemomab Ltd.
![]() Chemomab Ltd. BiotechnologyHealth Technology ChemomAb Ltd. develops novel chemokine blocking therapies for inflammatory and fibrotic disorders. It specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The company was founded by Adi Mor and Jacob George in 2011 and is headquartered Tel Aviv, Israel. | Director of Finance/CFO | 2020-09-30 | - |
Simbiz | Founder | 2020-08-31 | - |
TransPharma Medical Ltd.
![]() TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | Director of Finance/CFO | - | - |
Training of Sigal Fattal
Tel-Aviv University | Masters Business Admin |
Statistics
International
Israel | 9 |
Operational
Director of Finance/CFO | 6 |
Masters Business Admin | 1 |
Undergraduate Degree | 1 |
Sectoral
Health Technology | 6 |
Consumer Services | 2 |
Technology Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
EVOGENE LTD. | Health Technology |
CHEMOMAB THERAPEUTICS LTD. | Health Technology |
Private companies | 5 |
---|---|
TransPharma Medical Ltd.
![]() TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | Health Technology |
BiomX Ltd.
![]() BiomX Ltd. Pharmaceuticals: MajorHealth Technology BiomX Ltd. engages in the development of customized phage therapies designed to target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease and colorectalcancer, as well as bacteria that affect the appearance of the skin. The company was founded by Eran Elinav, Timothy K. Lu, and Rotem Sorek on March 3, 2015 and is headquartered in Ness Ziona, Israel. | Health Technology |
ECtel Ltd.
![]() ECtel Ltd. Information Technology ServicesTechnology Services ECtel, Ltd. engages in the development and marketing of fraud prevention and revenue assurance solutions for circuit-switched and packet-switched wireline and wireless networks. The company offers revenue assurance, fraud prevention and revenue assistance solutions, which consist of proprietary software and hardware components, as well as off-the-shelf hardware and software components. Its solutions equip telecommunications service providers with data gathering and analysis capabilities by detecting and preventing fraud; supporting revenue assurance, including call leakage detection; enabling to settle interconnect disputes between operators; monitoring network usage, and providing traffic trend reports. ECtel sells its products through its direct sales force and marketing staff, as well as through representatives, distributors and sales consultants in Israel, the Americas, Europe, Asia Pacific and other countries. The company, formerly known as ECI Telesystems, Ltd., was established in 1990 and is headquartered in Rosh Ha'ayin, IL. | Technology Services |
Simbiz | |
Chemomab Ltd.
![]() Chemomab Ltd. BiotechnologyHealth Technology ChemomAb Ltd. develops novel chemokine blocking therapies for inflammatory and fibrotic disorders. It specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The company was founded by Adi Mor and Jacob George in 2011 and is headquartered Tel Aviv, Israel. | Health Technology |
- Stock Market
- Insiders
- Sigal Fattal
- Experience